I’m a firm believer in the power of biotechnology and the promise it holds to develop products to transform our health and lives. Having had the privilege of conducting neuroscience bench research at UCSF, I have great respect for the life-saving and ground-breaking work that scientists do every day.
In the case of rare diseases, the biology is especially complex; and despite advances in medical science, the cell biology isn’t well understood. Recursion Pharmaceuticals, an early drug discovery company, aims to change that paradigm by bridging technology and biotechnology.
With a goal to discover treatments for those afflicted with rare diseases, Recursion Pharmaceuticals combines advances in machine learning, computer vision, and robotic automation to run experiments and perform analysis on hundreds of disease states simultaneously. The company creates hundreds of thousands of extremely detailed microscopic images of abnormal cells similar to those of genetic diseases, then uses image-recognition software to automatically seek an existing known compound that will make the cell look healthy again. Their computer vision algorithms aren’t too different from those at Google and Facebook that recognize faces or match images. The only difference here is that Recursion is looking for potential treatments among existing drugs and compounds that are already known to the medical research community and regulatory agencies. By using a tech approach with powerful software, Recursion’s high-throughput drug research methodology allows them to significantly reduce cycle times typically common in the life sciences and significantly scale their experiments.
Today, we announced that Recursion Pharmaceuticals is using Splunk® Enterprise and the Splunk Machine Learning Toolkit to help it reach its goal to discover treatments for 100 genetic diseases by 2025. We’re excited by the impact Recursion Pharmaceuticals is poised to have on the millions of people suffering from rare diseases for which no treatment currently exists.